For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| 2 Minute - 2 mg/kg Group | 2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol | 0 | None | 0 | 31 | 4 | 31 | View |
| 2 Minute - 1,5 mg/kg Group | 2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol | 0 | None | 0 | 30 | 1 | 30 | View |
| 2 Minute - 1 mg/kg Group | 2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol | 0 | None | 0 | 31 | 0 | 31 | View |
| 1 Minute - 2 mg/kg Group | 2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol | 0 | None | 0 | 31 | 2 | 31 | View |
| 1 Minute - 1,5 mg/kg Group | 2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol | 0 | None | 0 | 32 | 3 | 32 | View |
| 1 Minute - 1 mg/kg Group | 2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol | 0 | None | 0 | 31 | 0 | 31 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Vasoactive drug need | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |